$FROGNeutralLow

Simon Frederic sold $2.0M of FROG

Simon Frederic sold 22,436 shares of JFrog Ltd (FROG) at $87.62 ($1.97M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

7/10
6/10
Low
Neutral
Filed after-hours on 2026-06-03; may influence next session sentiment.
Neutral-to-slightly negative (insider selling), tempered by 10b5-1 pre-arrangement.

This is an insider selling disclosure; it may slightly affect near-term sentiment but does not signal a new fundamental catalyst by itself.

Director Simon Frederic sold $1.97M of JFrog shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Low likelihood of a sustained price move; any reaction is likely limited to intraday sentiment around the filing.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by a director with a pre-arranged 10b5-1 plan.

Why it matters

Traders may monitor whether insider selling accelerates or coincides with other negative catalysts, but this filing alone is not a fundamental update.

Market relevance

A routine insider sale disclosure for FROG; potential short-term sentiment impact, low fundamental significance.

Market effects

No direct sector read-through; insider selling under 10b5-1 is company-specific.

None indicated.

None indicated.

Alternative perspectives

10b5-1 sales can be purely scheduled liquidity events and may not reflect bearish expectations.

The disclosure does not include intent beyond the plan; without additional context (e.g., multiple consecutive sales), signal strength is limited.

Key entities

  • JFrog Ltd

    Subject of the insider transaction disclosure on SEC Form 4.

  • Simon Frederic

    Director who sold 22,436 shares under a pre-arranged 10b5-1 plan.

Related articles

$FROGLow

JFrog (FROG) Stock Is Up, What You Need To Know

JFrog (FROG) shares rose about 3% in the afternoon after Bank of America raised its price target to $100 from $85 and kept a Buy rating, following the stock’s re-rating after JFrog’s Q1 results on May 7. The article notes other firms (Oppenheimer, Morgan Stanley, UBS) also lifted targets after Q1, with full-year guidance cited at $630 million (midpoint).